- Home
- FOXX vs NXTC Comparison
FOXX vs NXTC Comparison
Compare FOXX & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FOXX
- NXTC
- Stock Information
- Founded
- FOXX 2017
- NXTC 2015
- Country
- FOXX United States
- NXTC United States
- Employees
- FOXX N/A
- NXTC N/A
- Industry
- FOXX
- NXTC Biotechnology: Pharmaceutical Preparations
- Sector
- FOXX
- NXTC Health Care
- Exchange
- FOXX Nasdaq
- NXTC Nasdaq
- Market Cap
- FOXX 30.5M
- NXTC 24.6M
- IPO Year
- FOXX N/A
- NXTC 2019
- Fundamental
- Price
- FOXX $4.00
- NXTC $12.60
- Analyst Decision
- FOXX
- NXTC Strong Buy
- Analyst Count
- FOXX 0
- NXTC 2
- Target Price
- FOXX N/A
- NXTC $25.50
- AVG Volume (30 Days)
- FOXX 24.5K
- NXTC 87.7K
- Earning Date
- FOXX 11-18-2025
- NXTC 11-04-2025
- Dividend Yield
- FOXX N/A
- NXTC N/A
- EPS Growth
- FOXX N/A
- NXTC N/A
- EPS
- FOXX N/A
- NXTC N/A
- Revenue
- FOXX $65,919,166.00
- NXTC N/A
- Revenue This Year
- FOXX N/A
- NXTC N/A
- Revenue Next Year
- FOXX N/A
- NXTC N/A
- P/E Ratio
- FOXX N/A
- NXTC N/A
- Revenue Growth
- FOXX 1941.75
- NXTC N/A
- 52 Week Low
- FOXX $2.45
- NXTC $2.69
- 52 Week High
- FOXX $11.00
- NXTC $19.20
- Technical
- Relative Strength Index (RSI)
- FOXX 37.13
- NXTC 71.81
- Support Level
- FOXX $4.09
- NXTC $8.51
- Resistance Level
- FOXX $4.78
- NXTC $12.39
- Average True Range (ATR)
- FOXX 0.26
- NXTC 1.61
- MACD
- FOXX 0.04
- NXTC 0.29
- Stochastic Oscillator
- FOXX 0.00
- NXTC 91.67
About FOXX Foxx Development Holdings Inc. Common Stock
Foxx Development Holdings Inc is a consumer electronics and integrated Internet-of-Things (IoT) solution company catering to both retail and institutional clients. With robust research and development capabilities and a strategic commitment to cultivating long-term partnerships with mobile network operators, distributors, and suppliers. Its products include tablets, smartphones, wearables, and other high-quality communication terminals.
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.